5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

 

5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology
J

Treatment Options for Newly Diagnosed Myeloma: Time to Incorporate CD38 Antibodies?

By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Jesus Berdeja
By 5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology FEATURING Jesus Berdeja
0 views
March 13, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Hematologic Malignancies
06:39
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Frontline Therapy in CLL: Obinutuzumab + Ibrutinib, Ibrutinib vs. Ch…

Feat. I. Flinn
07:09
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

ELEVATE TN Data on Acalabrutinib - Practice Changing Trial in CLL

Feat. I. Flinn
11:47
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options for Newly Diagnosed Myeloma: Time to Incorporate C…

Feat. J. Berdeja
09:00
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Treatment Options in R/R Multiple Myeloma: Tips for Selecting Among …

Feat. J. Berdeja
12:36
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Future Directions in Multiple Myeloma: Selinexor Approval, Venetocla…

Feat. J. Berdeja
18:23
5th Annual West Oncology Conference at Graceland: Advances in the Business of Science of Oncology

Time Limited Therapy in CLL, Ibrutinib vs Zanubrutinib in WM & L…

Feat. I. Flinn